+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Diabetes Drugs Market by Drug Class, Route of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032- Product Image
Diabetes Drugs Market by Drug Class, Route of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032- Product Image
Sale

Diabetes Drugs Market by Drug Class, Route of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032

  • Report

  • 197 Pages
  • June 2026
  • Region: Global
  • 360iResearch™
  • ID: 6083884
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Diabetes Drugs Market is projected to reach USD 113.04 Billion in 2026. It is expected to continue growing at a CAGR of 11.46%, reaching USD 217.45 Billion by 2032.

The diabetes drugs market is expanding as the global diabetes burden rises and treatment goals shift from glycemic control alone to broader cardiometabolic risk reduction. The International Diabetes Federation reported 537 million adults living with diabetes in 2021 and projected 643 million by 2030, creating sustained demand for insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, metformin, and fixed-dose combination therapies.

Growth is also being shaped by earlier diagnosis, broader reimbursement for high-value therapies, obesity-linked type 2 diabetes, and expanding use of continuous glucose monitoring. For industry leaders, competitive advantage increasingly depends on clinical differentiation, supply reliability, affordability, real-world evidence, and the ability to support lifelong diabetes management across diverse healthcare systems.

Transformative Shifts in Diabetes Drug Development

The diabetes treatment landscape is being transformed by therapies that address glucose control, weight management, cardiovascular outcomes, and kidney protection. GLP-1 receptor agonists and dual incretin therapies have reshaped prescribing patterns, while SGLT2 inhibitors have gained strong clinical relevance due to demonstrated cardiovascular and renal benefits in major outcomes trials.

At the same time, insulin delivery is moving toward more patient-centric formats, including connected pens, automated dosing support, and biosimilar insulin options. Market competition is shifting from single-product efficacy claims to integrated value propositions that combine clinical outcomes, adherence support, payer evidence, and scalable manufacturing capacity.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming an enabling layer across diabetes drug discovery, clinical development, commercialization, and patient support. AI models are used to identify drug targets, screen molecules, optimize trial design, stratify patients, and detect safety signals from real-world datasets, helping reduce uncertainty in diabetes drug development.

AI also strengthens diabetes care delivery through predictive analytics, remote monitoring, dose optimization, and adherence interventions. When integrated with continuous glucose monitoring, electronic health records, and pharmacy data, AI can support more personalized therapy selection while improving pharmacovigilance and market access evidence generation.

Key Regional Insights Across Global Diabetes Markets

Asia-Pacific is central to diabetes drug demand because China and India account for some of the world’s largest diabetes populations, supported by rising diagnosis rates, urbanization, and expanding access to modern therapies. Japan, Australia, and South Korea add value through advanced reimbursement systems, strong clinical adoption, and digital diabetes management.

North America remains a high-value region led by the United States, where CDC data show 38.4 million people had diabetes in 2021, while Canada emphasizes public reimbursement, cost-effectiveness, and equitable access. Latin America continues to face a rising type 2 diabetes burden, with Mexico and Brazil expanding access to insulin, oral antidiabetic drugs, and newer cardiometabolic therapies through public and private channels.

Europe is shaped by EMA approvals, national health technology assessment scrutiny, guideline-driven prescribing, and biosimilar adoption across insulin and injectable therapies. The Middle East, particularly high-income Gulf countries, shows strong demand linked to obesity, sedentary lifestyles, and investment in specialty diabetes care, while Africa presents substantial unmet need where affordability, diagnosis gaps, medicine availability, and cold-chain infrastructure remain decisive barriers.

Key Group Insights for Diabetes Drug Demand

ASEAN markets show rising demand for oral antidiabetic drugs, insulin, and newer injectable therapies as public health systems manage increasing type 2 diabetes prevalence and improve primary care screening. The GCC is characterized by high obesity-linked diabetes rates and strong demand for premium therapies, particularly in countries investing in specialty care, digital health infrastructure, and chronic disease prevention programs.

The European Union offers a harmonized regulatory pathway through the EMA, although market access depends on national reimbursement decisions, health technology assessments, and evidence on clinical value. BRICS markets provide scale, local manufacturing depth, and volume demand, with China, India, and Brazil playing especially important roles in access expansion and pharmaceutical production capacity.

G7 countries lead in innovation, clinical evidence generation, guideline adoption, and premium therapy uptake, supported by mature reimbursement systems and advanced diabetes care infrastructure. NATO markets place growing emphasis on supply-chain resilience, medicine security, and continuity of access for insulin, GLP-1 receptor agonists, SGLT2 inhibitors, and other essential antidiabetic therapies.

Key Country Insights in the Diabetes Drugs Market

The United States leads in diabetes drug innovation, GLP-1 uptake, clinical trial activity, and payer-driven outcomes evidence, supported by a large diagnosed population and established specialty care networks. Canada emphasizes public reimbursement, cost-effectiveness, and equitable access, while Mexico faces a high diabetes burden and continues to expand access to essential antidiabetic medicines and chronic disease management. Brazil represents a major Latin American pharmaceutical market where public procurement, private healthcare demand, and rising type 2 diabetes prevalence support continued use of insulin, oral therapies, and newer drug classes.

In Europe, the United Kingdom, Germany, France, Italy, and Spain balance clinical innovation with HTA requirements, budget controls, guideline-based prescribing, and biosimilar adoption. Germany and France remain influential for reimbursement and clinical practice standards, the United Kingdom emphasizes evidence-based access through national guidance, and Italy and Spain continue to manage diabetes demand through regional healthcare systems. Russia maintains demand for insulin and oral antidiabetic therapies under localization and supply-security pressures.

China and India drive volume demand due to large diabetes populations, rising diagnosis rates, and expanding access to branded, generic, and locally manufactured therapies. Japan supports advanced diabetes care through mature reimbursement and strong adoption of innovative therapies, while Australia combines public reimbursement with structured chronic disease management. South Korea is strengthening diabetes care through advanced healthcare infrastructure, digital health adoption, and increasing use of modern antidiabetic drug classes.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated portfolios that combine glucose control with weight, cardiovascular, and kidney benefits. Companies must invest in real-world evidence, head-to-head comparative data, patient adherence tools, and payer-relevant outcomes to support premium positioning for GLP-1 receptor agonists, SGLT2 inhibitors, insulin, and combination therapies.

Operationally, leaders should secure API sourcing, strengthen cold-chain reliability, expand biosimilar and affordable options, and localize access strategies by region. Partnerships with digital health firms, pharmacies, payers, and clinical networks can improve patient engagement and generate data that supports reimbursement, safety monitoring, and long-term brand trust.

Research Methodology

This executive summary is developed using a structured secondary-research framework covering epidemiology, regulatory approvals, treatment guidelines, clinical trial evidence, pharmacovigilance resources, reimbursement policies, and public health datasets. Core references include recognized sources such as the International Diabetes Federation, WHO, CDC, FDA, EMA, OECD, national health agencies, and peer-reviewed clinical literature.

The analysis triangulates disease prevalence, therapeutic class trends, regional access conditions, reimbursement dynamics, and innovation signals. Market interpretation emphasizes verified evidence, consistency across reputable sources, and practical relevance for pharmaceutical manufacturers, biotechnology organizations, payers, distributors, and healthcare strategy teams, while avoiding unsupported market sizing or forecasting assumptions.

Conclusion

The diabetes drugs market is entering a more sophisticated phase where efficacy, safety, affordability, supply assurance, and patient outcomes collectively define success. Demand is supported by a large and growing diabetes population, while therapeutic innovation is shifting care toward cardiometabolic and renal protection.

Organizations that align innovation with access will be best positioned to support long-term therapeutic adoption. Strong evidence generation, AI-enabled development, resilient manufacturing, digital engagement, and region-specific commercialization strategies will determine leadership in the global antidiabetic drugs market.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Diabetes Drugs Market, by Drug Class
7.1. Amylin Analogs
7.2. GLP-1 Receptor Agonists
7.3. Insulin
7.3.1. Long Acting
7.3.2. Short-Acting
7.4. Oral Antidiabetic Drugs (OADs)
8. Diabetes Drugs Market, by Route Of Administration
8.1. Inhalation
8.2. Injectable
8.3. Oral
9. Diabetes Drugs Market, by Diabetes Type
9.1. Type 1 Diabetes
9.2. Type 2 Diabetes
10. Diabetes Drugs Market, by Drug Origin
10.1. Branded Drugs
10.2. Generic Drugs
11. Diabetes Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Asia-Pacific Diabetes Drugs Market
13. Europe Diabetes Drugs Market
14. North America Diabetes Drugs Market
15. Latin America Diabetes Drugs Market
16. Africa Diabetes Drugs Market
17. Middle East Diabetes Drugs Market
18. NATO Diabetes Drugs Market
19. G7 Diabetes Drugs Market
20. BRICS Diabetes Drugs Market
21. European Union Diabetes Drugs Market
22. ASEAN Diabetes Drugs Market
23. GCC Diabetes Drugs Market
24. China Diabetes Drugs Market
25. United States Diabetes Drugs Market
26. Japan Diabetes Drugs Market
27. India Diabetes Drugs Market
28. Germany Diabetes Drugs Market
29. United Kingdom Diabetes Drugs Market
30. Australia Diabetes Drugs Market
31. France Diabetes Drugs Market
32. South Korea Diabetes Drugs Market
33. Italy Diabetes Drugs Market
34. Canada Diabetes Drugs Market
35. Russia Diabetes Drugs Market
36. Brazil Diabetes Drugs Market
37. Mexico Diabetes Drugs Market
38. Spain Diabetes Drugs Market
39. Competitive Landscape
39.1. Market Concentration Analysis, 2025
39.1.1. Concentration Ratio (CR)
39.1.2. Herfindahl Hirschman Index (HHI)
39.2. Recent Developments & Impact Analysis, 2025
39.3. Product Portfolio Analysis, 2025
39.4. Benchmarking Analysis, 2025
40. Company Profiles
40.1. Abbott Laboratories
40.2. Astellas Pharma Inc
40.3. AstraZeneca plc
40.4. Baxter International, Inc.
40.5. Bayer AG
40.6. Biocon Limited
40.7. Bioton S.A.
40.8. Boehringer Ingelheim International GmbH
40.9. Bristol Myers Squibb Company
40.10. Cipla Limited
40.11. Daiichi Sankyo Company Limited
40.12. Eli Lilly and Company
40.13. Eva Pharma
40.14. GlaxoSmithKline plc
40.15. Glenmark Pharmaceuticals Limited
40.16. Gulf Pharmaceutical Industries (Julphar)
40.17. Johnson and Johnson
40.18. Lupin Limited
40.19. MannKind Corporation
40.20. Merck & Co., Inc.
40.21. MJ Biopharm Pvt. Ltd.
40.22. Novartis AG
40.23. Novo Nordisk A S
40.24. Oramed Pharmaceuticals Inc.
40.25. Pfizer Inc
40.26. Roche Holding AG
40.27. Sanofi S A
40.28. Sun Pharmaceutical Industries Ltd
40.29. Takeda Pharmaceutical Company Limited
40.30. Teva Pharmaceutical Industries Ltd
40.31. Tonghua Dongbao Pharmaceutical Co., Ltd.
40.32. Viatris Inc.
40.33. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL DIABETES DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DIABETES DRUGS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DIABETES DRUGS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DIABETES DRUGS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 13. GLOBAL DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
FIGURE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 25. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. EUROPE DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 27. EUROPE DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 29. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 30. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 31. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 32. AFRICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 33. AFRICA DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 34. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 35. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 36. NATO DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 37. NATO DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 38. G7 DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 39. G7 DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 40. BRICS DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 41. BRICS DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 42. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 43. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 44. ASEAN DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 45. ASEAN DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 46. GCC DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 47. GCC DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 48. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 49. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 50. JAPAN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 51. INDIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 52. GERMANY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 53. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 54. AUSTRALIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 55. FRANCE DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 56. SOUTH KOREA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 57. ITALY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 58. CANADA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 59. RUSSIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 60. BRAZIL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 61. MEXICO DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 62. SPAIN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 7. GLOBAL DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AMYLIN ANALOGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GLP-1 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL INSULIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL INSULIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL INSULIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL LONG ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL LONG ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL LONG ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SHORT-ACTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SHORT-ACTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SHORT-ACTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ORAL ANTIDIABETIC DRUGS (OADS) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL INHALATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL INHALATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL INHALATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL INJECTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL INJECTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL INJECTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL BRANDED DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL BRANDED DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL BRANDED DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENERIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENERIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENERIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL RETAIL PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL RETAIL PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL RETAIL PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 63. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 64. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 65. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 66. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 67. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 68. EUROPE DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 70. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 71. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 72. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 73. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 74. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 82. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 89. AFRICA DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 91. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 92. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 93. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 94. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 95. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 102. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 103. NATO DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 104. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 105. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 106. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 107. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 108. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 109. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110. G7 DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 112. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 113. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 114. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 115. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 116. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 117. BRICS DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 120. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 121. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 122. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 123. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 127. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 130. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. ASEAN DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 133. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 134. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 136. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 137. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. GCC DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 139. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 140. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 141. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 143. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 144. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 146. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 147. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 148. CHINA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. CHINA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 150. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 151. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 153. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 154. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 155. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 157. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 158. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. JAPAN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 160. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 161. JAPAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 162. JAPAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. JAPAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 164. JAPAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 165. JAPAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. INDIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 167. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 168. INDIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 169. INDIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 170. INDIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 171. INDIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 172. INDIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. GERMANY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 174. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. GERMANY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 176. GERMANY DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 177. GERMANY DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 178. GERMANY DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 179. GERMANY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 181. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 182. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 183. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 187. AUSTRALIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 188. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 189. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 190. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 192. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 193. AUSTRALIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. FRANCE DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 195. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. FRANCE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 197. FRANCE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 198. FRANCE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 199. FRANCE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 200. FRANCE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 201. SOUTH KOREA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 202. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 203. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 204. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 206. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 207. SOUTH KOREA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 208. ITALY DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 209. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. ITALY DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 211. ITALY DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 212. ITALY DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 213. ITALY DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 214. ITALY DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 215. CANADA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 216. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 217. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 218. CANADA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. CANADA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 220. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 221. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. RUSSIA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 223. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. RUSSIA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 225. RUSSIA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 226. RUSSIA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 227. RUSSIA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 228. RUSSIA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 229. BRAZIL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 230. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 231. BRAZIL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 232. BRAZIL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 233. BRAZIL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 234. BRAZIL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 235. BRAZIL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 236. MEXICO DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 237. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 238. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 239. MEXICO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 240. MEXICO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 241. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 242. MEXICO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 243. SPAIN DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 244. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 245. SPAIN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
TABLE 246. SPAIN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247. SPAIN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
TABLE 248. SPAIN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
TABLE 249. SPAIN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The companies featured in this Diabetes Drugs market report include:
  • Abbott Laboratories
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Baxter International, Inc.
  • Bayer AG
  • Biocon Limited
  • Bioton S.A.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • Eva Pharma
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Gulf Pharmaceutical Industries (Julphar)
  • Johnson and Johnson
  • Lupin Limited
  • MannKind Corporation
  • Merck & Co., Inc.
  • MJ Biopharm Pvt. Ltd.
  • Novartis AG
  • Novo Nordisk A S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi S A
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedJune 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 113.04 Billion
Forecasted Market Value ( USD ) by 2032 $ 217.45 Billion
Compound Annual Growth Rate11.4%
Regions CoveredGlobal
No. of Companies Mentioned34

Related Topics

Related Reports

North America Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028) - Product Image

North America Diabetes Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)

  • Report
  • 150 Pages
  • North America
From
Asia-Pacific Diabetes Care Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029 - Product Image

Asia-Pacific Diabetes Care Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

  • Report
  • 90 Pages
  • Asia Pacific
From
Diabetes Drugs - Global Strategic Business Report - Product Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • 478 Pages
  • Global
From
Type 2 Diabetes Drugs Market - Global Forecast 2026-2032 - Product Image

Type 2 Diabetes Drugs Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Antidiabetic Drugs Market - Global Forecast 2026-2032 - Product Image

Antidiabetic Drugs Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From

About the Diabetes Drugs Market

The Diabetes Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat diabetes. Diabetes is a chronic condition that affects millions of people worldwide, and the drugs used to treat it can help to manage the symptoms and reduce the risk of complications. Commonly prescribed diabetes drugs include insulin, sulfonylureas, meglitinides, thiazolidinediones, and DPP-4 inhibitors. These drugs are used to help regulate blood sugar levels, reduce insulin resistance, and improve the body's ability to use insulin. Some of the major companies in the Diabetes Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the research, development, and marketing of diabetes drugs, and they are constantly striving to develop new and improved treatments for the condition. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.